Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 4/20 | 0.47 |
| ▸ | HTR1A | P08908 | 5/20 | 0.45 |
| ▸ | DRD2 | P14416 | 5/20 | 0.45 |
| ▸ | HTR2A | P28223 | 5/20 | 0.45 |
| ▸ | HTR7 | P34969 | 2/20 | 0.44 |
| ▸ | HTR6 | P50406 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2981140 | 0.92 | CTSS (0.55) | CTSSHTR1ADRD2HTR2AHTR7 | |
| SCHEMBL5252008 | 0.89 | HTR2A (0.45) | CTSSHTR1ADRD2HTR2AHTR7 | |
| SCHEMBL2978841 | 0.89 | CTSS (0.49) | CTSSHTR1ADRD2HTR2AHTR7 | |
| SCHEMBL2979193 | 0.85 | CTSS (0.59) | CTSSHTR1ADRD2HTR2A | |
| SCHEMBL5252279 | 0.83 | HTR1A (0.43) | CTSSHTR1ADRD2HTR2AHTR7 | |
| SCHEMBL2981307 | 0.82 | HTR2A (0.47) | CTSSHTR1ADRD2HTR2AHTR7 | |
| SCHEMBL2981133 | 0.79 | CTSS (0.52) | CTSSDRD2 | |
| SCHEMBL14107676 | 0.76 | CTSS (0.58) | CTSS | |
| SCHEMBL5534589 | 0.74 | CTSS (0.75) | CTSS | |
| SCHEMBL5541145 | 0.73 | CTSS (0.75) | CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772236-B2 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2010-08-10 | — | — | US | claimed |
| US-20080293732-A1 | Substituted pyrazoles | BEAVERS MARY PAT | 2008-11-27 | — | — | US | claimed |
| US-7429591-B2 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2008-09-30 | — | — | US | claimed |
| US-7309703-B2 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2007-12-18 | — | — | US | claimed |
| EP-1309591-B1 | SUBSTITUTED PYRAZOLES | ORTHO MCNEIL PHARM INC (US) | 2007-01-24 | — | — | EP | claimed |
| US-20070004747-A1 | Inhibiting the proteolytic activity of cathepsin S; 1-[4-(2-Amino-6-chloro-phenyl)-piperazin-1-yl]-3-[5-methanesulfonyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-propan-2-ol; antiarthritic agent; autoimmune disease: lupus, rheumatoid arthritis, and asthma | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2007-01-04 | — | — | US | claimed |
| EP-1315491-B1 | USE OF SUBSTITUTED PYRAZOLES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF ALLERGIES | ORTHO MCNEIL PHARM INC (US) | 2006-08-09 | — | — | EP | claimed |
| EP-1315491-A2 | METHOD FOR TREATING ALLERGIES USING SUBSTITUTED PYRAZOLES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-06-04 | — | — | EP | claimed |
| EP-1309591-A2 | SUBSTITUTED PYRAZOLES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-05-14 | — | — | EP | claimed |
| US-20030073672-A1 | Method for treating allergies using substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2003-04-17 | — | — | US | claimed |
| US-20030069240-A1 | Method for treating allergies using substituted pyrazoles | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-04-10 | — | — | US | claimed |
| US-20020040020-A1 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2002-04-04 | — | — | US | claimed |
| WO-2002020012-A2 | METHOD FOR TREATING ALLERGIES USING SUBSTITUTED PYRAZOLES | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-03-14 | — | — | WO | claimed |
| WO-2002014314-A2 | SUBSTITUTED PYRAZOLES | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-02-21 | — | — | WO | claimed |
| US-7772236-B2 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772236-B2 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772236-B2 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-20030069240-A1 | Method for treating allergies using substituted pyrazoles | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-04-10 | — | — | US | disclosed |
| US-20020040020-A1 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2002-04-04 | — | — | US | disclosed |
| WO-2002014314-A2 | SUBSTITUTED PYRAZOLES | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293732-A1 | Substituted pyrazoles | CTSS, CTSZ, CTSB | CTSS 1/4885HTR1A 4383/4885DRD2 4859/4885 |
| US-20030069240-A1 | Method for treating allergies using substituted pyrazoles | TSLP, IL33, HRH2 | CTSS 294/4885HTR1A 1182/4885DRD2 3703/4885 |
| US-20030073672-A1 | Method for treating allergies using substituted pyrazoles | TSLP, IL33, HRH2 | CTSS 294/4885HTR1A 1182/4885DRD2 3703/4885 |
| US-20070004747-A1 | Inhibiting the proteolytic activity of cathepsin S; 1-[4-(2-Amino-6-chloro-phenyl)-piperazin-1-yl]-3-[5-methanesulfonyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-propan-2-ol; antiarthritic agent; autoimmune disease: lupus, rheumatoid arthritis, and asthma | CTSS, CTSV, CTSZ | CTSS 1/4885HTR1A 1721/4885DRD2 4380/4885 |
| US-20020040020-A1 | Substituted pyrazoles | CTSS, CTSZ, CTSV | CTSS 1/4885HTR1A 4279/4885DRD2 4815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.